SG
RCKT icon

Sankala Group’s Rocket Pharmaceuticals RCKT Stock Holding History

Sankala Group’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.21K Hold
828
– – ﹤0.01% 465
2025
Q4 		$4.15K Buy
+828
New +$2.83K ﹤0.01% 461

Other funds holding RCKT

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Sankala Group's RCKT Position: Q1 2026 in Review

Sankala Group held its Rocket Pharmaceuticals (RCKT) position steady in Q1 2026 at 828 shares worth $3.21K. The position accounts for ﹤0.01% of the portfolio, ranked #465.

Sankala Group first reported a position in RCKT in Q4 2025 and has held it in 2 quarters since. The position peaked at $4.15K in Q4 2025. 199 funds tracked by Wall St. Rank hold RCKT as of Q1 2026.

  • Sankala Group held 828 shares of Rocket Pharmaceuticals worth $3.21K as of Q1 2026.
  • Sankala Group left its Rocket Pharmaceuticals share count unchanged in Q1 2026.
  • Rocket Pharmaceuticals made up ﹤0.01% of Sankala Group's portfolio in Q1 2026, its #465 holding.
  • Sankala Group first reported a position in Rocket Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • Sankala Group's Rocket Pharmaceuticals position peaked at $4.15K in Q4 2025.
  • 199 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q1 2026.

Based on Sankala Group's 13F filing for Q1 2026, filed 31 Mar 2026.